论文部分内容阅读
目的:探讨曲美他嗪联合参麦注射液对冠心病心力衰竭患者的疗效。方法:选择该院2014年3月至2015年4月接受治疗的70例冠心病心力衰竭患者,随机分为对照组和观察组,每组各35例。两组均接受常规疗法,对照组加用曲美他嗪,观察组则在对照组基础上加用参麦注射液,比较两组左室射血分数、血浆脑钠肽变化情况及临床总有效率。结果:治疗后,观察组临床总有效率为94.74%明显高于对照组78.95%;观察组左室射血分数显著高于对照组(P<0.05),差异均具有统计学意义。结论:曲美他嗪联合参麦注射液治疗冠心病心力衰竭可有效改善患者心功能,减低血浆脑钠肽水平,提高临床疗效,值得推广。
Objective: To investigate the effect of trimetazidine combined with shenmai injection on patients with coronary heart disease and heart failure. Methods: Seventy patients with CHD who were treated in our hospital from March 2014 to April 2015 were randomly divided into control group and observation group, 35 cases in each group. Both groups received routine therapy, the control group plus trimetazidine, the observation group was added to the control group on the basis of Shenmai injection, compared two groups of left ventricular ejection fraction, changes in plasma brain natriuretic peptide and clinical total effectiveness. Results: After treatment, the total effective rate in the observation group was 94.74%, which was significantly higher than 78.95% in the control group. The left ventricular ejection fraction in the observation group was significantly higher than that in the control group (P <0.05). The differences were statistically significant. Conclusion: Trimetazidine combined with Shenmai injection in the treatment of heart failure with coronary heart disease can effectively improve the cardiac function, reduce the level of plasma brain natriuretic peptide and improve the clinical curative effect, which deserves promotion.